Discontinued — last reported Q4 '24

Operating

Non Cash Acquired In Process Research And Development

Over 2 years (FY 2021 to FY 2024), Non Cash Acquired In Process Research And Development shows a downward trend with a -100.0% CAGR.

Analysis

StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2020
Last reportedQ4 2024May 29, 2025

How to read this metric

Higher values indicate significant investment in future pipeline growth through acquisitions rather than internal development.

Detailed definition

This represents the non-cash expense associated with the acquisition of in-process research and development assets. It r...

Peer comparison

Common in biopharma companies that frequently acquire early-stage assets or spin-out entities.

Metric ID: operating_non_cash_acquired_in_process_research_and_development

Historical Data

13 periods
 Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24
Value$19.56M$19.56M$19.56M$19.56M$21.94M$21.94M$21.94M$21.94M$0.00$0.00$0.00$0.00$0.00
QoQ Change+0.0%+0.0%+0.0%+12.2%+0.0%+0.0%+0.0%-100.0%
YoY Change+12.2%+12.2%+12.2%+12.2%-100.0%
Range$0.00$21.94M
CAGR-100.0%
Avg YoY Growth-10.3%
Median YoY Growth+12.2%

Frequently Asked Questions

What is Roivant Sciences's non cash acquired in process research and development?
Roivant Sciences (ROIV) reported non cash acquired in process research and development of $0.00 in Q1 2025.
What is the long-term trend for Roivant Sciences's non cash acquired in process research and development?
Over 2 years (2021 to 2024), Roivant Sciences's non cash acquired in process research and development has grown at a -100.0% compound annual growth rate (CAGR), from $78.22M to $0.00.
What does non cash acquired in process research and development mean?
Non-cash costs related to acquiring unfinished research projects.